Reference number : GC-2017-Q3-00531, amendment number : , agreement type : G, recipient legal name : Nekkar Rao, Praveen (University of Waterloo), recipient country : CA, recipient province : nan, recipient city : Ontario, recipient postal code : nan, program name english : Engage Grants for universities, program name french : Subventions d'engagement partenarial pour les universités, program purpose english : One of the key functions of kidneys is to separate uremic toxins from the blood. Currently, dialysis is the main_x000D_
technique of separation of uremic toxins from blood. In this regard, End Stage Renal Disease (ESRD) is a_x000D_
global health concern with a high prevalence percentage (15% - global; 30% - Canada). The leading treatment_x000D_
for ESRD patients is hemodialysis, where the blood is passed through a semipermeable membrane and the_x000D_
uremic toxins diffuse into the dialysate. This is a repetitive, laborious, time consuming and expensive process._x000D_
Qidni Labs Inc., Kitchener, Ontario is developing renal replacement therapies that will eliminate the necessity_x000D_
of dialysis clinic sessions and will administer continuous and automatic renal therapy. In this proposal Qidni_x000D_
Labs Inc. and Dr. Praveen Nekkar Rao (Associate Professor, School of Pharmacy, University of Waterloo) are_x000D_
collaborating to investigate alternative methods of separating uremic toxins using a novel microfluidic platform_x000D_
and their detection using analytical tools. This proposal aims to investigate novel methods of separating uremic_x000D_
toxins using a novel microfluidic platform and their detection using analytical tools. The outcomes are_x000D_
anticipated to reveal the mechanisms of small molecule separation using the microfluidic technology and their_x000D_
potential application to kidney patients in Canada thereby providing health and economic benefits to_x000D_
Canadians., program purpose french : One of the key functions of kidneys is to separate uremic toxins from the blood. Currently, dialysis is the main_x000D_
technique of separation of uremic toxins from blood. In this regard, End Stage Renal Disease (ESRD) is a_x000D_
global health concern with a high prevalence percentage (15% - global; 30% - Canada). The leading treatment_x000D_
for ESRD patients is hemodialysis, where the blood is passed through a semipermeable membrane and the_x000D_
uremic toxins diffuse into the dialysate. This is a repetitive, laborious, time consuming and expensive process._x000D_
Qidni Labs Inc., Kitchener, Ontario is developing renal replacement therapies that will eliminate the necessity_x000D_
of dialysis clinic sessions and will administer continuous and automatic renal therapy. In this proposal Qidni_x000D_
Labs Inc. and Dr. Praveen Nekkar Rao (Associate Professor, School of Pharmacy, University of Waterloo) are_x000D_
collaborating to investigate alternative methods of separating uremic toxins using a novel microfluidic platform_x000D_
and their detection using analytical tools. This proposal aims to investigate novel methods of separating uremic_x000D_
toxins using a novel microfluidic platform and their detection using analytical tools. The outcomes are_x000D_
anticipated to reveal the mechanisms of small molecule separation using the microfluidic technology and their_x000D_
potential application to kidney patients in Canada thereby providing health and economic benefits to_x000D_
Canadians., agreement title english : Investigating the mechanisms of small molecule separation in blood plasma, agreement title french : Investigating the mechanisms of small molecule separation in blood plasma, agreement number : EGP, agreement value : 25000.0, agreement start date : 2017-10-18, agreement end date : nan, description english : nan, description french : nan, expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year (2017-2018 to 2018-2019)., additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier (2017-2018 à 2018-2019)., owner organization : nserc-crsng, owner organization title : Natural Sciences and Engineering Research Council of Canada | Conseil de recherches en sciences naturelles et en génie du Canada